Loading…

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells

Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel,...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1995-06, Vol.71 (6), p.1194-1198
Main Authors: Hennequin, C, Giocanti, N, Favaudon, V
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773
cites
container_end_page 1198
container_issue 6
container_start_page 1194
container_title British journal of cancer
container_volume 71
creator Hennequin, C
Giocanti, N
Favaudon, V
description Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel, cytotoxicity increased with progression through S and G2, peaked at the time of mitosis, and decreased thereafter. Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at prometaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily targets centrosome organisation, leading to abortive mitosis and cell death.
doi_str_mv 10.1038/bjc.1995.232
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2033844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>7779710</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773</originalsourceid><addsrcrecordid>eNptkE1LAzEQhoMoWj9uXoUcPCi4dbKb3SQXQcQvKHjw4xqy6WybumZLsor990ZbioKnYXifeQceQg4ZDBkU8rye2SFTqhzmRb5BBqws8ozJXGySAQCIDFQOO2Q3xllaFUixTbaFEEowGJCXx2w-NRFpnKN1jbOuX9CuoRbblr66tnV-QusFHXcWe_OJLT15Mp9djwFPqfM0Lrydhs67iGN6hyPzcxn3yVZj2ogHq7lHnm-un67ustHD7f3V5SiznFd9Juvc5FDxkhtZqRolL4TAMda8rjiUYCopG5SSqaphDI2yFXDkpVEMrBSi2CMXy975e_2GY4u-D6bV8-DeTFjozjj9N_Fuqifdh86hKCTnqeBsWWBDF2PAZn3LQH_r1Umv_tark96EH_3-t4ZXPlN-vMpNtKZtgvHWxTVWlLysQCUsW2IxJX6CQc-69-CTqf_ffgFeqJIu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells</title><source>PubMed Central</source><creator>Hennequin, C ; Giocanti, N ; Favaudon, V</creator><creatorcontrib>Hennequin, C ; Giocanti, N ; Favaudon, V</creatorcontrib><description>Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel, cytotoxicity increased with progression through S and G2, peaked at the time of mitosis, and decreased thereafter. Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at prometaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily targets centrosome organisation, leading to abortive mitosis and cell death.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1995.232</identifier><identifier>PMID: 7779710</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Antineoplastic agents ; Antineoplastic Agents, Phytogenic - toxicity ; Biological and medical sciences ; Biological Transport ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cell Cycle - drug effects ; Cell Division - drug effects ; Cell Survival - drug effects ; Docetaxel ; Drug Resistance ; Epidemiology ; experimental-oncology ; General aspects ; HeLa Cells ; Humans ; Kinetics ; Medical sciences ; Molecular Medicine ; Oncology ; Paclitaxel - analogs &amp; derivatives ; Paclitaxel - metabolism ; Paclitaxel - toxicity ; Pharmacology. Drug treatments ; S Phase ; Taxoids ; Time Factors ; Tritium ; Tumor Stem Cell Assay</subject><ispartof>British journal of cancer, 1995-06, Vol.71 (6), p.1194-1198</ispartof><rights>Cancer Research Campaign 1995</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033844/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033844/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3545609$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7779710$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hennequin, C</creatorcontrib><creatorcontrib>Giocanti, N</creatorcontrib><creatorcontrib>Favaudon, V</creatorcontrib><title>S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel, cytotoxicity increased with progression through S and G2, peaked at the time of mitosis, and decreased thereafter. Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at prometaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily targets centrosome organisation, leading to abortive mitosis and cell death.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - toxicity</subject><subject>Biological and medical sciences</subject><subject>Biological Transport</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Division - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Docetaxel</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>experimental-oncology</subject><subject>General aspects</subject><subject>HeLa Cells</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Paclitaxel - analogs &amp; derivatives</subject><subject>Paclitaxel - metabolism</subject><subject>Paclitaxel - toxicity</subject><subject>Pharmacology. Drug treatments</subject><subject>S Phase</subject><subject>Taxoids</subject><subject>Time Factors</subject><subject>Tritium</subject><subject>Tumor Stem Cell Assay</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNptkE1LAzEQhoMoWj9uXoUcPCi4dbKb3SQXQcQvKHjw4xqy6WybumZLsor990ZbioKnYXifeQceQg4ZDBkU8rye2SFTqhzmRb5BBqws8ozJXGySAQCIDFQOO2Q3xllaFUixTbaFEEowGJCXx2w-NRFpnKN1jbOuX9CuoRbblr66tnV-QusFHXcWe_OJLT15Mp9djwFPqfM0Lrydhs67iGN6hyPzcxn3yVZj2ogHq7lHnm-un67ustHD7f3V5SiznFd9Juvc5FDxkhtZqRolL4TAMda8rjiUYCopG5SSqaphDI2yFXDkpVEMrBSi2CMXy975e_2GY4u-D6bV8-DeTFjozjj9N_Fuqifdh86hKCTnqeBsWWBDF2PAZn3LQH_r1Umv_tark96EH_3-t4ZXPlN-vMpNtKZtgvHWxTVWlLysQCUsW2IxJX6CQc-69-CTqf_ffgFeqJIu</recordid><startdate>19950601</startdate><enddate>19950601</enddate><creator>Hennequin, C</creator><creator>Giocanti, N</creator><creator>Favaudon, V</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19950601</creationdate><title>S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells</title><author>Hennequin, C ; Giocanti, N ; Favaudon, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - toxicity</topic><topic>Biological and medical sciences</topic><topic>Biological Transport</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Division - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Docetaxel</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>experimental-oncology</topic><topic>General aspects</topic><topic>HeLa Cells</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Paclitaxel - analogs &amp; derivatives</topic><topic>Paclitaxel - metabolism</topic><topic>Paclitaxel - toxicity</topic><topic>Pharmacology. Drug treatments</topic><topic>S Phase</topic><topic>Taxoids</topic><topic>Time Factors</topic><topic>Tritium</topic><topic>Tumor Stem Cell Assay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hennequin, C</creatorcontrib><creatorcontrib>Giocanti, N</creatorcontrib><creatorcontrib>Favaudon, V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hennequin, C</au><au>Giocanti, N</au><au>Favaudon, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1995-06-01</date><risdate>1995</risdate><volume>71</volume><issue>6</issue><spage>1194</spage><epage>1198</epage><pages>1194-1198</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel, cytotoxicity increased with progression through S and G2, peaked at the time of mitosis, and decreased thereafter. Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at prometaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily targets centrosome organisation, leading to abortive mitosis and cell death.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>7779710</pmid><doi>10.1038/bjc.1995.232</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 1995-06, Vol.71 (6), p.1194-1198
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2033844
source PubMed Central
subjects Antineoplastic agents
Antineoplastic Agents, Phytogenic - toxicity
Biological and medical sciences
Biological Transport
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cell Cycle - drug effects
Cell Division - drug effects
Cell Survival - drug effects
Docetaxel
Drug Resistance
Epidemiology
experimental-oncology
General aspects
HeLa Cells
Humans
Kinetics
Medical sciences
Molecular Medicine
Oncology
Paclitaxel - analogs & derivatives
Paclitaxel - metabolism
Paclitaxel - toxicity
Pharmacology. Drug treatments
S Phase
Taxoids
Time Factors
Tritium
Tumor Stem Cell Assay
title S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T07%3A34%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=S-phase%20specificity%20of%20cell%20killing%20by%20docetaxel%20(Taxotere)%20in%20synchronised%20HeLa%20cells&rft.jtitle=British%20journal%20of%20cancer&rft.au=Hennequin,%20C&rft.date=1995-06-01&rft.volume=71&rft.issue=6&rft.spage=1194&rft.epage=1198&rft.pages=1194-1198&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1995.232&rft_dat=%3Cpubmed_cross%3E7779710%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/7779710&rfr_iscdi=true